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Similar results were observed using three different anti-
LKB antibodies (results not shown). These results sug-Inactivating mutations in the protein kinase LKB1 lead
gest that LKB1 accounts for the majority of AMPKKto a dominantly inherited cancer in humans termed
activity purified from rat liver. We have not found anyPeutz-Jeghers syndrome [1, 2]. The role of LKB1 is
evidence to suggest that AMPK and LKB1 activitiesunclear, and only one target for LKB1 has been identi-
coimmunoprecipitate (results not shown).fied in vivo [3]. AMP-activated protein kinase (AMPK)
AMPK is heterotrimeric, consisting of an  catalyticis the downstream component of a protein kinase cas-
subunit and two regulatory subunits,  and , and iso-cade that plays a pivotal role in energy homeostasis
forms of all three subunits have been identified [4]. In[4]. AMPK may have a role in protecting the body from
rat, complexes containing the 1 subunit account formetabolic diseases including type 2 diabetes [5, 6],
the majority of AMPK activity in most tissues [11]. Weobesity [7], and cardiac hypertrophy [8]. We previously
previously showed that recombinant LKB1 purified fromreported the identification of three protein kinases
mammalian cells phosphorylates and activates AMPK(Elm1, Pak1, and Tos3 [9]) that lie upstream of Snf1,
111 [9]. LKB1 also activates the other major formsthe yeast homologue of AMPK. LKB1 shares sequence
of AMPK, and we did not detect any significant differ-similarity with Elm1, Pak1, and Tos3, and we demon-
ence in the activation of these complexes by LKB1 (Fig-strated that LKB1 phosphorylates AMPK on the activa-
ure 2A). LKB1 phosphorylated catalytically inactive mu-tion loop threonine (Thr172) within the catalytic subunit
tants of AMPK on Thr172 within the subunit (Figure 2B),and activates AMPK in vitro [9]. Here, we have investi-
and we have previously reported that phosphorylation ofgated whether LKB1 corresponds to the major AMPKK
AMPK requires LKB1 catalytic activity [9]. Taken to-activity present in cell extracts. AMPKK purified from
gether, these results strongly suggest that LKB1 acts byrat liver corresponds to LKB1, and blocking LKB1 ac-
directly phosphorylating AMPK rather than promotingtivity in cells abolishes AMPK activation in response
autophosphorylation of AMPK. Catalytically inactiveto different stimuli. These results identify a link be-
AMPK, which is unable to autophosphorylate, was phos-tween two protein kinases, previously thought to lie
phorylated to a stoichiometry of approximately 0.4 mol/in unrelated, distinct pathways, that are associated
mol by LKB1. Partially purified rat liver AMPKK waswith human diseases.
reported to be activated by AMP [12], but another study
failed to detect this effect [13]. We did not detect any
Results and Discussion effect of AMP on the ability of LKB1 to phosphorylate
and activate AMPK (Figures 2A and 2B). Using the same
LKB1 (also known as STK11) protein copurified with reagents, recombinant AMPK was activated allosteri-
AMPKK activity during two successive chromatography cally by AMP (results not shown), consistent with an
steps of the purification procedure [10]. Western blot earlier study we have previously reported [14]. We do
analysis of fractions from the Q-Sepharose ion ex- not know the reason for the difference between our
results and those of Hawley et al. [12], although there
are a number of explanations that could account for this*Correspondence: dcarling@csc.mrc.ac.uk
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Figure 1. LKB1 Is the Major AMPK Kinase Activity in Rat Liver
Partially purified AMPKK isolated from rat liver was fractionated by (A) ion-exchange chromatography on Q-Sepharose and (B) gel filtration
on Superdex-200. Fractions (2 l) were assayed for AMPKK by activation of recombinant AMPK (open squares) and protein (closed circles).
The elution position of molecular mass standards from the gel-filtration column is indicated by arrows, and the peak fraction number of
AMPKK activity in each case is labeled. In parallel, aliquots (25 l) were analyzed by Western blotting using anti-LKB1 antibodies, and fractions
across the peak of AMPKK activity are shown. No LKB1 crossreactivity was detected in any of the other fractions (results not shown). (C)
The peak fraction of AMPKK activity from Superdex-200 was incubated in the presence or absence of protein phosphatase 2C (0.16 mg/ml)
for 30 min at 37C before Western blot analysis with anti-LKB1 antibody. The migration of molecular mass standards is shown. (D and E)
AMPKK purified through the Q-Sepharose step was incubated with anti-LKB1 antibodies or sheep IgG immunoglobulins (Sigma) as a control.
(D) AMPKK activity present in the immune complexes was determined by activation of recombinant AMPK. Results are expressed as AMPK
activity and are the mean values SEM from three independent experiments. (E) AMPKK activity remaining in the supernatant after immunopre-
cipitation is plotted as a percentage of the initial activity before incubation with antibody. The values shown are the mean  SEM from four
independent experiments. We were unable to determine whether all of the AMPKK activity in the preparation could be accounted for by LKB1,
since repeated incubation with control antibody led to nonspecific but substantial depletion of AMPKK activity (results not shown). One unit
of AMPKK activity is the amount that increased the activity of recombinant AMPK by 1 nmol/min/mg.
discrepancy. For instance, it is possible that a factor tion, which leads to a concomitant increase in the
AMP:ATP ratio [4]. AMPK is also activated in responserequired to mediate the stimulation of LKB1 by AMP
was present in the partially purified AMPKK preparation, to treatments that do not alter adenine nucleotide levels,
e.g., incubation with the anti-diabetic agent metforminbut it is either not present in the expression system or
it is lost during the immunoprecipitation procedure used and hyperosmotic stress [16]. AMPK can be activated by
pharmacological manipulation using the cell-permeableto isolate recombinant LKB1 in our study. Clearly, further
work is required to investigate the effect of AMP on adenosine analog 5-amino-4-imidazolecarboxamide
(AICA) riboside, which is phosphorylated to ZMP, anphosphorylation of AMPK by LKB1.
LKB1 is phosphorylated by a number of protein ki- AMP mimetic [17]. To examine whether LKB1 activity is
regulated, we immunoprecipitated LKB1 from lysates ofnases at distinct sites, although the role of phosphoryla-
tion on LKB1 activity is unclear [15]. AMPKK activity H-2Kb muscle cells treated with stimuli known to alter
AMPK activity [16]. LKB1 activity did not change signifi-is known to be unaffected by incubation with different
protein phosphatases [10]. Consistent with this result, cantly in response to any of the conditions tested (Figure
2C), even though AMPK activity varied substantially (Fig-incubation of LKB1 with a mixture of protein phospha-
tases 1, 2A, and 2C had no effect on its ability to activate ure 2D). These results suggest that LKB1 is constitutively
active and are consistent with a previous study thatAMPK (results not shown).
In cells, AMPK is activated in response to ATP deple- reported constitutive AMPKK activity in a pancreatic 
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Figure 2. Regulation of LKB1
LKB1 expressed in COS7 cells was immuno-
precipitated with anti-FLAG resin and used
to phosphorylate recombinant AMPK com-
plexes in vitro. (A) AMPK activity after incuba-
tion with recombinant LKB1 in the presence
(shaded bars) or absence (open bars) of 0.2
mM AMP or in the absence of LKB1 (hatched
bars) is shown. AMPK assays were carried
out in the presence of 0.2 mM AMP, and the
results shown are the average values from
duplicate experiments that varied by less
than 10%. (B) Catalytically inactive forms of
AMPK (111 or 211 complexes) were
incubated in the presence or absence of re-
combinant LKB1 in the presence or absence
of 0.2 mM AMP. Thr172 phosphorylation was
determined by Western blot analysis using an
anti-phosphothreonine 172 (P-T172)-specific
antibody and total AMPK with an anti-1 spe-
cific antibody. (C and D) H-2Kb cells were in-
cubated in the presence or absence of 0.5 M
sorbitol, 0.5 mM dinitrophenol (DNP), 0.5 mM
AICA riboside (AICAR), 0.5 mM hydrogen per-
oxide (H2O2), or 2 mM metformin for 30 min
prior to harvesting and lysis. (C) LKB1 and (D)
AMPK activities were determined in immune
complexes isolated after immunoprecipita-
tion from 100 g total protein with anti-LKB1
or anti-AMPK antibodies. Results shown are
the mean values  SEM from four experi-
ments.
cell line [13]. We cannot exclude, however, the possibil- possible that inhibition of Hsp90 affects AMPK by some
other mechanism.ity that the conditions used here cause phosphorylation
or other modifications of LKB1 that are lost upon subse- We next sought to modulate LKB1 activity in a specific
manner using a genetic approach. We expressed wild-quent isolation, and hence no augmentation of activity
or effect of phosphatases is observed. type LKB1 or a catalytically inactive form of LKB1 har-
boring a mutation of aspartic acid residue 194 to alanineTo determine whether levels of LKB1 activity correlate
with AMPK activity, we examined various cell lines in- (D194A) in CCL13 cells. Expression of wild-type LKB1
caused a modest increase in AMPK activity relative tocluding two tumor cell lines, HeLa S3 (cervical carci-
noma) and G361 (melanoma), which have been reported cells transfected with a control vector (expressing
-galactosidase) (Figure 4A). In contrast, expression ofto express very low or undetectable levels of LKB1
mRNA and protein [18] (Figures 3A and 3B). We detected mutant LKB1 (D194A) completely abolished activation
of AMPK in response to either hydrogen peroxide orLKB1 activity in all of the cell lines, and there was a
remarkably close correlation between LKB1 activity and hyperosmotic stress. Under these conditions, there was
no detectable alteration in AMPK protein expression,AMPK activity in all cases (Pearson correlation coeffi-
cient of 0.945, p  0.005). In contrast, AMPK protein as judged by Western blotting with an anti-AMPK 
antibody (Figure 4B). These results indicate that catalyti-expression, as judged by Western blot analysis (Figure
3C), did not correlate with LKB1 or AMPK activity, indi- cally inactive LKB1 acts in a dominant-negative manner,
blocking AMPK activation and providing direct evidencecating that the differences in AMPK activity are due to
posttranslational effects. that LKB1 functions to activate AMPK in cells. Further-
more, since AMPK activation was abolished after treat-LKB1 has been reported to associate with a number
of proteins including heat-shock protein (Hsp) 90, which ment of the cells with either hydrogen peroxide, which
activates AMPK via an increase in the AMP:ATP ratioappears to be required for LKB1 stabilization [19]. Inhibi-
tors of Hsp90, such as geldanamycin and radicicol, de- [20], or hyperosmotic stress, which activates AMPK by
a nucleotide-independent pathway [16], these resultscrease LKB1 expression and activity in cells [19]. We
tested the effect of radicicol on AMPK activity. Incuba- demonstrate that LKB1 mediates both signaling path-
ways. Expression of catalytically inactive LKB1 did nottion of COS7 cells for 24 hr with 5M radicicol decreased
LKB1 activity by 80%, from 60.1  3.5 to 12.3  1.1 result in a complete loss of AMPK activity (Figure 4A).
One potential explanation for this observation is thatU/mg (n  6). AMPK activity was also reduced by as
much as 70% after activation by hyperosmotic stress expression of catalytically inactive LKB1 does not lead
to total inhibition of endogenous LKB1. Alternatively, it(0.5 M sorbitol), while AMPK protein expression was
unchanged (Figures 3D and 3E). Thus, this effect of is possible that another kinase, capable of activating
AMPK under basal conditions, is present in the cells,radicicol on AMPK activity is consistent with a role for
LKB1 in activating AMPK in vivo, although it remains and we are currently investigating this possibility.
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Figure 3. Reduced LKB1 Activity Is Associ-
ated with Decreased AMPK Activity
(A) Lysates (500 g total protein) from the
indicated cell lines were incubated with anti-
LKB1 antibodies, and LKB1 activity in the im-
mune complexes was determined by activa-
tion of recombinant AMPK.
(B and C) In parallel, (B) AMPK activity in anti-
AMPK immunoprecipitates (from 100 g to-
tal protein) was measured and (C) AMPK ex-
pression determined by Western blot analysis
using anti-AMPK antiserum.
(D) COS7 cells were incubated in the pres-
ence or absence of 5 M radicicol for 24 hr.
Cells were incubated with no added reagent
(control), 1 mM H2O2, or 0.5 M sorbitol for
15 min prior to harvesting. AMPK activity in
immune complexes isolated from 100g total
protein was determined. Results shown are
the average values of duplicate experiments
that varied by less than 10%.
(E) A representative Western blot showing
AMPK expression.
Conclusions cellular senescence [23]. It is intriguing that LKB1 has
been implicated in both of these processes [24], and inOur findings show that LKB1 is the major upstream ki-
nase in the AMPK cascade in mammalian cells. We do the light of our recent findings, it will be important to
investigate the role of AMPK in cancer.not exclude, however, the possibility of additional up-
stream kinases that activate AMPK in response to stimuli
Supplemental Dataother than those tested in our current study. The pres-
Supplemental Data including experimental procedures are availableence of other upstream kinases might explain our finding
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